Prosight reports shared ownership of 399,900 ADC Therapeutics (ADCT) shares.
Prosight Management, LP, Prosight Partners, LLC, and W. Lawrence Hawkins reported shared beneficial ownership of 399,900 common shares of ADC Therapeutics SA (ADCT), representing 0.31% of the class. This disclosure was made in a SCHEDULE 13G/A SEC filing, with the percentage based on 127,667,695 common shares outstanding as of August 3, 2026. The filing indicates shared voting and dispositive power over these shares, while Prosight Fund, LP and Prosight Plus Fund, LP reported zero beneficial ownership.
A proposed shareholder resale would bring ADC Therapeutics (ADCT) no proceeds.
ADC Therapeutics (ADCT) is registering a resale offering of up to 61 million common shares by selling shareholders, including shares from a private placement and those issuable from pre-funded warrants. The company will not receive any proceeds from these resales, though it could gain up to CHF 3.8 million if the pre-funded warrants are exercised in cash for working capital. This S-3 registration also details recent loan and royalty agreement amendments designed to improve the company's financial flexibility.
ADC Therapeutics Releases Q3 2026 Financial Results
ADC Therapeutics SA reported a loss per share of $0.06 for Q3 2026, with a net loss of $8.8 million, demonstrating ongoing investment in its antibody drug conjugate platform. Despite the loss, the company generated $21.7 million in revenue, a 32.1% increase from Q3 2025, indicating growing commercial traction for its targeted cancer treatments. Wall Street analysts maintain a generally positive outlook, with 4 buy and 3 hold ratings.
ADC Therapeutics (ADCT) Stock Price, Chart & Analysis
This article provides a detailed analysis of ADC Therapeutics (ADCT) stock, including its current price, market capitalization, and key financial figures. It highlights that the company pays no dividend and has negative margins and a weak Belegger score, indicating it's not currently profitable. The analysis also includes analyst forecasts for revenue growth and various price scenarios.
ADCT: ADC Therapeutics SA filed SEC Form 8-K: Results of Operations...
ADC Therapeutics (ADCT) reported its Q3 2026 results, showing a rise in net product revenue to $21.0 million from $15.8 million year-over-year. The company also significantly narrowed its net loss to $25.3 million from $41.0 million, and extended its cash runway into 2029 following a restructuring. Despite a continued net loss, the filing highlighted positive indicators for shareholders through increased sales and reduced operating expenses.
Form 8K ADC Therapeutics SA For: 9 November By Investing.com
This article reports on ADC Therapeutics SA's Form 8K filing for November 9, 2026, as published by Investing.com. The filing is a regulatory disclosure often used to announce significant events that shareholders should know about. The article also notes a 5.70% increase in ADC Therapeutics (ADCT) stock.
ADC Therapeutics SA (ADCT) Q3 Revenue Rose to $21.0M; Restructuring Extends Runway Into 2029
ADC Therapeutics SA (ADCT) reported a significant increase in Q3 net product revenue to $21.0 million, up from $15.8 million in Q3 2025, with a narrowed net loss of $25.3 million. The company's cash position was $189.2 million at September 30, and a recent October restructuring is expected to extend its cash runway into 2029. This financial update also includes details on an $86.6 million PIPE financing and a reduction in senior loan principal.
ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates
ADC Therapeutics (NYSE: ADCT) reported its Q3 2026 financial results, with net product revenue reaching $21 million and cash and cash equivalents of $189.2 million. The company completed a strategic financial restructuring that extended its cash runway into 2029 and announced multiple ZYNLONTA® abstracts, including five oral presentations, for the upcoming ASH 2026 meeting, highlighting its potential in B-cell malignancies. Additionally, its Japanese partner, Tanabe Pharma, submitted a marketing authorization application for ZYNLONTA and entered a sublicensing agreement for commercialization in Japan.
ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Data at ASH and Strategic Financial Restructuring - Slideshow
ADC Therapeutics SA (ADCT) has published a slide deck detailing its ZYNLONTA data presented at ASH and its strategic financial restructuring efforts. The company's presentation provides insights into its recent developments and future plans regarding its key therapeutic asset. This information is available for investors and interested parties to review.
AIGH Capital Management LLC Acquires New Shares in ADC Therapeutics SA $ADCT
AIGH Capital Management LLC has purchased a new stake of 4.32 million shares in ADC Therapeutics SA (NYSE:ADCT), valued at approximately $5.28 million, representing 3.39% of the company. Other institutional investors also adjusted their holdings. ADC Therapeutics recently reported a quarterly EPS loss of $0.11, beating analysts' estimates, and revenue of $19.25 million, also exceeding expectations, though shares were reported down 4.9%.
ADC Therapeutics SA (ADCT) Latest Stock News & Headlines
This Yahoo Finance page provides the latest news and headlines for ADC Therapeutics SA (ADCT), a biopharmaceutical company. The content includes a series of press releases and news articles from various sources detailing financial results, upcoming presentations, drug program updates for ZYNLONTA®, and strategic financial restructuring. It also shows ADCT's recent stock performance compared to the S&P 500.
FDA Approval for ZYNLONTA issued to ADC Therapeutics SA
The FDA has issued an approval for Supplement SUPPL-15 to ZYNLONTA's Biologic License Application (BLA) 761196 for ADC Therapeutics SA. The action date for this approval was November 4, 2026, though the specific changes introduced by the supplement have not yet been disclosed. ZYNLONTA (loncastuximab tesirine) was originally approved on April 23, 2021.
ADC Therapeutics Reports Strong Lymphoma Responses, Plans Phase III Study
ADC Therapeutics reported strong data for its cancer drug ZYNLONTA in lymphoma, outlining results from the LOTIS-7 combination study and a marginal zone lymphoma study. The company plans a Phase III study for the ZYNLONTA-glofitamab combination and is seeking breakthrough therapy designation for its use in marginal zone lymphoma. Financially, ADC Therapeutics reported preliminary third-quarter sales of approximately $21 million and expects a cash runway into 2029 following a recent restructuring and private investment.
ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program
ADC Therapeutics has announced that new and updated data from its ZYNLONTA® (loncastuximab tesirine-lpyl) clinical program will be presented at the 68th American Society of Hematology (ASH) Annual Meeting. The presentations will feature five oral presentations and multiple posters, showcasing the depth and durability of ZYNLONTA across various B-cell lymphomas and treatment settings. Key highlights include promising results from the LOTIS-7 study for r/r DLBCL, robust and durable responses in marginal zone lymphoma, and statistically significant improvement in PFS in the Phase 3 LOTIS-5 study for r/r DLBCL.
ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program
ADC Therapeutics (NYSE: ADCT) announced that new and updated data from its ZYNLONTA® (loncastuximab tesirine-lpyl) clinical program will be presented at the 68th American Society of Hematology (ASH) Annual Meeting. The data, featured in five oral presentations and multiple posters, highlight the depth and durability of response observed with ZYNLONTA across various B-cell lymphomas, including difficult-to-treat patient populations. Key presentations include updated results from the Phase 1b LOTIS-7 study of ZYNLONTA plus glofitamab in r/r DLBCL, showing an 88.7% ORR and 75.3% CRR, and data from a Phase 2 investigator-initiated trial demonstrating a 93% ORR and 74.4% CRR with ZYNLONTA monotherapy in r/r marginal zone lymphoma.
ADC Therapeutics to Present at November Investor Conferences
ADC Therapeutics SA (NYSE: ADCT) announced its participation in two investor conferences in November 2026. CEO Ameet Mallik will present at the Guggenheim Third Annual Healthcare Innovation Conference on November 10th and the Jefferies Global Healthcare Conference on November 19th. The company, a leader in antibody drug conjugates, will provide webcasts and replays of these presentations on its investor relations website.
ADC Therapeutics (ADCT) Projected to Announce Quarterly Earnings on Tuesday
ADC Therapeutics (ADCT) is expected to announce its Q3 2026 earnings before market open on Tuesday, November 10th, with analysts projecting a loss of $0.21 per share and revenue of $18.69 million. The company exceeded expectations in its previous quarter. Despite a recent 2.3% share increase to $1.57, analysts maintain a consensus "Hold" rating with a $5.00 price target.
ADC Therapeutics to Present at November Investor Conferences
ADC Therapeutics SA announced its participation in two upcoming investor conferences in November: the Guggenheim Third Annual Healthcare Innovation Conference on November 10, 2026, and the Jefferies Global Healthcare Conference on November 19, 2026. Ameet Mallik, the Chief Executive Officer, will speak at both events, which will be available via live webcasts on the company's investor relations website. The company, a leader in antibody drug conjugates (ADCs), will provide replays of the webcasts for approximately 30 days.
ADC Therapeutics Awards 17,000 Stock Options to New Hire Under Inducement Plan
ADC Therapeutics SA (NYSE:ADCT) announced the grant of options to purchase 17,000 common shares to a new employee on November 2, 2026. This grant serves as a material inducement for employment and was approved under the company's Inducement Plan and NYSE Listed Company Manual Rule 303A.08. The options have a four-year vesting schedule, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter, contingent on continued employment.
ADC Therapeutics Must Show Lotus 7 Can Carry The Story After Lotus 5's FDA Setback
ADC Therapeutics faces a critical moment as it heads into its third-quarter report, needing to demonstrate that its Lotus 7 strategy can succeed after its Lotus 5 growth driver encountered FDA regulatory issues. The company must provide clear updates on Lotus 7's regulatory path and show evidence of cost savings to maintain investor confidence following a significant stock rebound from a previous low. The market is looking for concrete plans to replace lost catalysts and validate its pivot.
ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026
ADC Therapeutics SA (NYSE: ADCT) announced that it will release its full financial results for the third quarter of 2026 on Monday, November 9, 2026, via a press release. The announcement will be available on the company's investor relations website. ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates, known for its product ZYNLONTA®.
ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026
ADC Therapeutics SA (NYSE: ADCT) announced it will release its full financial results for the third quarter of 2026 on Monday, November 9, 2026. The press release will be available in the News section of the Company's website. ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates, known for ZYNLONTA® for relapsed or refractory diffuse large B-cell lymphoma.
ADC Therapeutics SA (NYSE:ADCT) Stock Rated "Hold" by Sell-Side Analysts
Sell-side analysts have issued a consensus "Hold" rating for ADC Therapeutics SA (NYSE:ADCT), with an average 12-month price target of $5.00. The company recently surpassed quarterly earnings expectations, reporting a smaller loss per share and higher revenue than projected. Institutional investors currently hold 41.1% of the stock.
ADC Therapeutics SA (ADCT) Seasonal returns chart
The article displays a seasonal returns chart for ADC Therapeutics SA (ADCT), showing the average monthly price return from 2020 to 2026. As of the market close on October 30, ADCT stock was priced at $1.53, with pre-market trading indicating a slight increase.
ADC Therapeutics partner files for Japan approval of ZYNLONTA
ADC Therapeutics announced that its Japanese licensing partner, Tanabe Pharma Corporation, has filed a marketing authorization application with Japan’s Ministry of Health, Labor and Welfare for ZYNLONTA. The application seeks approval for ZYNLONTA to treat patients with relapsed or refractory diffuse large B-cell lymphoma. This filing is based on positive results from a Phase 1/2 bridging study in Japanese patients, which showed an overall response rate of 58.1% and a complete response rate of 41.9%.
Bain Capital reports 7 million shares plus warrants in ADC Therapeutics (ADCT).
Bain Capital Life Sciences Opportunities IV, L.P. has reported a beneficial ownership of 14,825,625 common shares, or 9.99%, in ADC Therapeutics SA (ADCT) as of October 22, 2026. This includes 7,000,000 common shares and pre-funded warrants allowing the purchase of up to 22,703,927 common shares, though a 9.99% beneficial ownership blocker limits the exercisable amount. The filing details key figures, terms, and the calculation of the ownership percentage based on outstanding shares and a recent private placement.
ADC Therapeutics Announces ZYNLONTA® Updates in Japan
ADC Therapeutics announced that its Japanese licensing partner, Tanabe Pharma, has filed a marketing authorization application for ZYNLONTA (loncastuximab tesirine-lpyl) in Japan to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Tanabe Pharma also sublicensed commercialization rights to Nippon Shinyaku. This follows encouraging Phase 1/2 clinical results in Japanese patients, consistent with the global LOTIS-2 study.
ADC Therapeutics' partner files for Zynlonta approval in Japan
ADC Therapeutics announced that its Japanese licensing partner, Tanabe Pharma Corporation, has filed a marketing authorization application for Zynlonta in Japan. The application seeks approval for Zynlonta to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and is based on positive results from a Phase 1/2 bridging study in Japanese patients. Tanabe Pharma has also sublicensed the commercialization rights for Zynlonta in Japan to Nippon Shinyaku Co., Ltd.
ADC Therapeutics SA Estimates – NYSE:ADCT
This article provides an overview of ADC Therapeutics SA (NYSE:ADCT) financial estimates and data available on TradingView. It highlights sections like income statement, balance sheet, cash flow, and valuation metrics, allowing users to compare actual results with analyst estimates. The platform offers tools for exploring reported financial data and visualizing trends over time.
ADC Therapeutics secures USD 86.6 million PIPE for ADC Therapeutics stock
ADC Therapeutics has secured an $86.6 million private investment in public equity (PIPE) deal, which includes 12.9 million common shares and 48.1 million pre-funded warrants. This financing, along with a broader restructuring that removes a $150 million payment and prepays $70 million of a loan, is expected to extend the company's cash runway into 2029. The deal aims to fund ZYNLONTA pipeline studies but introduces a clear dilution factor due to the share issuance and warrants.
ADC Therapeutics secures $86.6M financing, restructures debt By Investing.com
ADC Therapeutics SA has announced an $86.6 million private placement and debt restructuring that is expected to extend its cash runway into 2029. The company secured investments from Bain Capital Life Sciences, Redmile, TCGX, and Nantahala Capital, and also amended agreements with HealthCare Royalty Management and Blue Owl Opportunistic Master Fund I to reduce future payment obligations and debt. The proceeds will fund ZYNLONTA pipeline studies, including Phase 3 trials for diffuse large B-cell lymphoma and marginal zone lymphoma.
ADC Therapeutics buys time for Zynlonta with $86.6M financing
ADC Therapeutics has secured an $86.6 million financing deal and amended existing debt and royalty agreements, extending its cash runway into 2029. This financial maneuver aims to support the development of its lymphoma drug, Zynlonta, and provides greater flexibility following challenges with its LOTIS-5 Phase 3 trial. The restructuring also removes a potential obstacle to a future takeover by eliminating a large change-of-control payment.
ADC Therapeutics secures $86.6M financing, restructures debt By Investing.com
ADC Therapeutics (NYSE:ADCT) has secured $86.6 million in a private placement and restructured its debt, extending its cash runway into 2029. The financing involves selling common shares and pre-funded warrants to institutional investors, including Bain Capital Life Sciences and existing investors. The company also amended agreements with HealthCare Royalty Management and Blue Owl Opportunistic Master Fund I, which includes a $70 million prepayment of term loans and elimination of certain covenants, to strengthen its financial position and fund ZYNLONTA pipeline studies.
ADC Therapeutics secures $86.6M financing, restructures debt By Investing.com
ADC Therapeutics SA has secured $86.6 million in new financing through a private placement and restructured its debt, extending its cash runway into 2029. The deal involves selling common shares and pre-funded warrants to institutional investors including Bain Capital Life Sciences, and amending agreements with HealthCare Royalty Management and Blue Owl Opportunistic Master Fund I. These moves aim to reduce future payment obligations, lower third-party indebtedness limits, and provide funds for ZYNLONTA pipeline studies.
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics (NYSE: ADCT) has announced a comprehensive strategic financial restructuring to strengthen its balance sheet, reduce leverage, and extend its cash runway into 2029. The restructuring includes an $86.6 million private placement with new and existing investors, an amended financing agreement with HealthCare Royalty that removes a change-of-control payment, and the refinancing of a senior secure loan, decreasing its principal to $50 million with a bullet payment in August 2029. These initiatives are expected to increase the company's strategic optionality as it approaches significant data readouts in the coming months.
ADC Therapeutics raises $86.6M in PIPE, restructures debt
ADC Therapeutics SA announced a financial restructuring including an $86.6 million private placement, amendments to its royalty agreement with HealthCare Royalty, and a reduction of its senior secured loan to $50 million. The PIPE participants include Bain Capital Life Sciences and existing investors. These actions are expected to fund Phase 3 clinical trials for ZYNLONTA and extend the company's cash runway into 2029.
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics (NYSE: ADCT) has announced a comprehensive strategic financial restructuring to bolster its balance sheet, reduce debt, and extend its cash runway into 2029. The plan includes an $86.6 million private placement with new and existing investors, amendments to the HealthCare Royalty financing agreement to remove a change-of-control payment, and refinancing of a senior secure loan to decrease the principal to $50 million with no minimum liquidity requirement. These actions aim to enhance strategic optionality as the company anticipates important clinical data releases in the coming months.
ADC Therapeutics secures $86.6M financing, restructures debt
ADC Therapeutics (NYSE:ADCT) has secured $86.6 million in new financing and restructured its debt, extending its cash runway into 2029. The deal includes a private placement with institutional investors and amendments to existing loan agreements, reducing liabilities and providing capital for pipeline studies. The company reported preliminary Q3 net product revenues of $21 million for ZYNLONTA.
ADC Therapeutics stock gained 8.27 percent to USD 1.38
ADC Therapeutics (ADCT) stock increased by 8.27% to USD 1.38 on October 7, 2026, trading 72.3% below its yearly high. The company reported Q2 2026 revenue of USD 19.2 million and held USD 219.1 million in cash, with analysts maintaining a consensus "Hold" rating and an average price target of USD 5.00. The next earnings report is scheduled for November 10, 2026.
ADC Therapeutics stock gained 4.63 percent as analysts held Hold consensus
ADC Therapeutics (ADCT) stock increased by 4.63% on October 2, 2026, closing at USD 1.13, despite a Hold consensus from analysts. The company reported Q2 revenue of USD 19.25 million and a narrower-than-expected adjusted loss of USD 0.11 per share. Analysts' average 12-month price target is USD 5.00, significantly above the current price, indicating potential sensitivity to the clinical and regulatory progress of its drug, ZYNLONTA, which faces regulatory risk due to adverse events in clinical trials.
ADC Therapeutics SA (NYSE:ADCT) Receives Average Recommendation of "Hold" from Brokerages
ADC Therapeutics SA (NYSE:ADCT) has received an average "Hold" rating from six brokerages, with an average 12-month price target of $5.00. The company recently reported an adjusted loss of $0.11 per share and $19.25 million in revenue, surpassing analyst estimates. Institutional investors and hedge funds currently own 41.1% of the stock.
ADC Therapeutics (NYSE:ADCT) Stock Price Down 4.9% - Time to Sell?
ADC Therapeutics (ADCT) shares dropped 4.9% to $1.29 on Tuesday, with trading volume significantly below its average. Despite the price dip, the company reported a narrower-than-expected quarterly loss and exceeded revenue estimates. Analyst sentiment is generally a "Hold" with an average price target of $5.00, suggesting potential upside, and institutional investors are increasing their holdings.
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
ADC Therapeutics (NYSE: ADCT) announced that CEO Ameet Mallik will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on September 11, 2026, at 9:10 a.m. ET. A live webcast and replay of the presentation will be available on the company's investor relations website. The company is a leader in antibody drug conjugates (ADCs) with its approved drug ZYNLONTA®.
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
ADC Therapeutics SA announced that its CEO, Ameet Mallik, will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on September 11, 2026. The event will be webcast live and a replay will be available for 30 days. ADC Therapeutics is a commercial-stage company focusing on antibody drug conjugates (ADCs) with its product ZYNLONTA® for treating relapsed or refractory diffuse large B-cell lymphoma.
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
ADC Therapeutics SA announced that its CEO, Ameet Mallik, will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on September 11, 2026. A live webcast of the event will be available on the company's investor relations website, with a replay accessible for approximately 30 days. ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates, known for its product ZYNLONTA.
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
ADC Therapeutics (NYSE: ADCT) announced that its CEO, Ameet Mallik, will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on September 11, 2026, at 9:10 a.m. ET. A live webcast and replay of the event will be available on the Investors section of their website. The company also provided a brief overview of its work as a commercial-stage global leader in antibody drug conjugates, specifically ZYNLONTA® for relapsed or refractory diffuse large B-cell lymphoma.
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
ADC Therapeutics (NYSE: ADCT) reported its second quarter 2026 financial results, including net product revenue of $18.6 million and cash equivalents of $219.1 million as of June 30, 2026. The company discussed its regulatory strategy for ZYNLONTA®, including ongoing evaluation for full approval and advancement into earlier lines of DLBCL, following an FDA meeting on LOTIS-5 data. Enrollment for the LOTIS-7 trial is complete, showing promising combination data for ZYNLONTA plus glofitamab, leading to assessment of a Phase 3 trial and potential Breakthrough Therapy designation.
ADC Therapeutics Number of Employees 2026 | Employee Count & Headcount Data
ADC Therapeutics SA (ADCT) had approximately 203 employees worldwide as of March 2026, marking a 27.5% decline from 280 employees in 2023. The company is actively hiring, with 12 job postings in 2026, a 120% increase from 2025. Its workforce is primarily concentrated in North America (75.2%), and the average salary is $217,829, with employee sentiment rated as neutral but improving.
ADC Therapeutics SA (NYSE:ADCT) Given Consensus Rating of "Hold" by Brokerages
ADC Therapeutics SA (NYSE:ADCT) has received a consensus "Hold" rating from six brokerages, with an average 12-month price target of $5.00. The company recently reported a quarterly loss of $0.11 per share, beating analyst estimates, and revenue of $19.25 million, which slightly exceeded expectations. Institutional investors hold approximately 41.1% of the stock.
ADC Therapeutics (NYSE:ADCT) Rating Increased to Hold at Wall Street Zen
Wall Street Zen upgraded ADC Therapeutics (NYSE:ADCT) from a "sell" to a "hold" rating. The company reported a quarterly loss of $0.11 per share, beating analyst estimates, with revenue of $19.25 million also exceeding expectations. Despite mixed analyst coverage, the stock has a consensus "hold" rating and an average target price of $6.25, with institutional investors owning approximately 41.1% of the shares.